GlaxoSmithKline plc (GSK) Given New GBX 1760 Price Target at Berenberg Bank

Cornelia Mascio
Novembre 15, 2017

Risk Paradigm Group, LLC divested its stake by selling 50 shares a decrease of 4.0% in the quarter.

Here are a few institutional investors who have updated their positions.

GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings results on Wednesday, October 25th. Risk Paradigm Group, LLC owns 1,200 shares valued at $48,720,000. Keystone Financial Planning, Inc. augmented its holdings by buying 2,210 shares an increase of 1.7% from 06/30/2017 to 09/30/2017. CIBC World Markets Inc. now owns 434,538 shares of the pharmaceutical company's stock worth $18,833,000 after buying an additional 102,460 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in shares of GlaxoSmithKline PLC by 2.7% in the second quarter. The brokerage now has a "buy" rating on the stock.

WARNING: "GlaxoSmithKline plc's (GSK) "Hold" Rating Reaffirmed at Deutsche Bank AG" was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company's stock valued at $137,000 after buying an additional 64 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price.

GlaxoSmithKline plc (LON GSK) traded up GBX 1 ($0.01) on Thursday, reaching GBX 1,319 ($17.35). That compares with the recent volume average of 3.09 million. GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%.

The company now has an insider ownership of 0.2 Percent and Institutional ownership of 9.8 Percent. The stock has a market cap of $94.62 billion, a P/E ratio of 259.27 and a beta of 0.90.

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be given a dividend of $0.5037 per share. The ex-dividend date was Wednesday, November 2nd. This represents a $2.01 dividend on an annualized basis and a yield of 5.77%. Trading volume for GlaxoSmithKline plc was 5.18 Million in its previous trading session. GlaxoSmithKline PLC's dividend payout ratio is 163.12%.

A number of brokerages have recently issued reports on GSK. Beaufort Securities reaffirmed a "buy" rating and set a GBX 1,800 ($23.67) target price on shares of GlaxoSmithKline plc in a report on Monday, October 23rd.

On October 24, 2017 J P Morgan Chase & Co maintained a "Neutral" rating on the company. BidaskClub downgraded GlaxoSmithKline PLC from a "sell" rating to a "strong sell" rating in a research note on Monday, July 24th. Bank of America Corporation lowered shares of GlaxoSmithKline PLC from a "buy" rating to a "neutral" rating in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of "Hold" and an average price target of GBX 1,574.25 ($20.71).

In related news, insider Urs Rohner acquired 473 shares of the business's stock in a transaction dated Wednesday, October 25th. The total value of its holdings decreased 9.6%. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 10.00% of the company's stock. If you are reading this news story on another domain, it was copied illegally and republished in violation of United States & worldwide copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/glaxosmithkline-plc-gsk-receives-neutral-rating-from-citigroup-inc/1771334.html. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK?

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE